Application of 3-substituted naphtho [2, 3-b] isoxazole-4, 9-diketone derivative in resisting psoriasis

Through the development of 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives, the problems of viral side effects and poor efficacy of existing psoriatic drugs have been solved, and by inhibiting STAT3 and inflammatory factors achieved significant anti-psoria effects and demonstrated potential therapeutic potential for tumors.

CN118903118AActive Publication Date: 2024-11-08CENT SOUTH UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410871302.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-01
Publication Date
2024-11-08
Estimated Expiration
2044-07-01

AI Technical Summary

Technical Problem

The existing psoriatic drugs have toxic side effects or poor efficacy, and the cause of psoriasis is complex, the pathogenesis is unclear, and there is a lack of effective targeted treatment methods.

Method used

Developing 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives, through their significant HaCaT proliferation inhibitory activity and downregulate STAT3 levels as a new anti-psoria drug Targets inhibit the activation of STAT3 and the production of inflammatory factors IL-17A and IL-17F.

Benefits of technology

It significantly inhibits the activation of STAT3 and produces inflammatory factors, has significant anti-psoria effects, is better than the traditional drug Anthralin, and IC50 reaches the nanomolar level, showing potential potential for the treatment of psoriasis and tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903118A_ABST
    Figure CN118903118A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of dermatological drugs, and relates to an application of a 3-substituted naphtho [2, 3-b] isoxazole-4, 9-diketone derivative in resisting psoriasis, the structural formula of the 3-substituted naphtho [2, 3-b] isoxazole-4, 9-diketone derivative is as shown in the general formula (I): # imgabs0 #, X is selected from oxygen or sulfur atoms; y and Z are independently selected from carbon or nitrogen atoms; the substitution definitions of R1 and R2 are shown in the specification. The 3-substituted naphtho [2, 3-b] isoxazole-4, 9-diketone derivative disclosed by the invention has remarkable HaCaT proliferation inhibition activity, the cell activity of part of compounds is 10 times or more higher than that of a positive reference substance, and IC50 even reaches a nano-friction level. According to the present invention, the P-STAT3 level can be significantly down-regulated, the activation process of the STAT3 is inhibited in the dose-dependent manner, the inhibition ability is superior to the inhibition ability of the reference substance STA21, and the animal experiment results show that the psoriasis resistance effect is superior to the drug anthranin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of dermatological drugs and relates to the application of 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives in anti-psoriasis. Background Art

[0002] Psoriasis is an immune-mediated chronic inflammatory skin disease, and the incidence of psoriasis has been increasing year by year in recent years. At the same time, psoriasis patients often have various complications, such as metabolic syndrome, obesity, cardiovascular disease, diabetes and psoriatic arthritis, which seriously endanger people's health and even shorten their lifespan.

[0003] Clinically, small molecule chemical drugs for the treatment of psoriasis mainly include glucocorticoids, vitamin D analogs, cyclosporine and methotrexate. However, these drugs have serious shortcomings such as toxic side effects or poor efficacy. Therefore, it is of great significance to study new anti-psoriasis drugs.

[0004] Targeted drugs are the key research direction for psoriasis drugs. The etiology of psoriasis is extremely complex, and the pathogenesis is still unclear. It is mainly affected by genetic, environmental, and immune factors. Psoriasis is characterized by persistent inflammation, which leads to uncontrolled proliferation and dysfunctional differentiation of keratinocytes (KC). It is an inflammatory autoimmune disease dominated by CD4+Th cells (Th17) that produce interleukin (IL)-17. Its formation is related to abnormal activation and local infiltration of T cells, excessive proliferation and abnormal differentiation of keratinocytes (KC), and abnormal proliferation of dermal microvessels. In this process, excessive activation of transduction and transcription activator 3 (STAT3) is an important cause of psoriasis. Therefore, STAT3 plays a key role in the onset of psoriasis and is a potential new target for the treatment of psoriasis. Abnormal activation of STAT3 in KC of patients with psoriasis may have the following mechanism of action: when the skin is damaged or infected, dendritic cells are activated by releasing antimicrobial peptides, thereby producing cytokines such as interleukin IL-6 and IL-23, which in turn activate STAT3, promote the production of IL-21 and form an IL-21 / STAT3 autocrine loop, promoting the differentiation of Th17 cells; mature Th17 cells produce proinflammatory factors such as IL-17 and IL-22, which activate STAT3 in keratinocytes (KC), causing them to overproliferate and abnormally differentiate, produce autoantigen K17, and further activate T cells to form a positive feedback pathway, promoting the occurrence and development of psoriasis. Summary of the invention

[0005] The purpose of the present invention is to provide the use of 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivatives in the preparation of anti-psoriasis drugs.

[0006] In order to achieve the above object, the technical solution of the present invention is as follows:

[0007] The use of 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives in the preparation of anti-psoriasis drugs, wherein the structural formula of the 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives is shown in general formula (I):

[0008]

[0009] Wherein, X is selected from oxygen or sulfur atom; Y and Z are independently selected from carbon or nitrogen atom;

[0010] R1 is selected from hydrogen, C1-C8 straight chain or branched alkyl, C3-C8 cycloalkyl, aryl, substituted aryl, substituted C1-C8 straight chain or branched alkyl, substituted C3-C8 cycloalkyl; the substituents on the substituted aryl, substituted C1-C8 straight chain or branched alkyl and substituted C3-C8 cycloalkyl are selected from halogen, amino, nitro, carboxyl, phenyl, benzyl, =O, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy, carboxyl, ester, aminoethoxy, aminopropoxy, aminobutoxy.

[0011] R2 is selected from hydrogen, hydroxyl, C1-C8 alkanoyloxy, halogen, C1-C8 alkyl, nitro, amine, and amino; the number of R2 is 1-4, and any substitution is at positions 1-4.

[0012] In one preferred embodiment, R1 is selected from C1-C5 straight chain or branched chain alkyl, halogenated C1-C5 straight chain or branched chain alkyl.

[0013] In a preferred embodiment, R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, and halogenated tert-pentyl.

[0014] In a preferred embodiment, R1 is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0015] Aryl refers to: (1) an aromatic monocyclic or condensed ring; preferably an aromatic carbocyclic ring (a ring structure in which all the ring atoms are carbon) having 5-12 carbon atoms. Examples of aryl include, but are not limited to, phenyl and naphthyl; (2) partially saturated carbocyclic rings may be connected, for example, phenyl and C5-7 cycloalkyl or C5-7 cycloalkenyl groups are fused to form a ring structure. Examples include, but are not limited to, tetrahydronaphthyl, indenyl or hydroindenyl.

[0016] In one preferred embodiment, R1 is selected from substituted phenyl. The structure of the substituted phenyl is: The number of substituents R5 on the substituted phenyl group is 1-5, and R5 is selected from halogen, amino, nitro, carboxyl, ester, phenyl, benzyl, =O, halogenated alkyl, C1-C5 straight chain or branched alkyl, amine-substituted C1-C5 straight chain or branched alkoxy, alkenyl, alkynyl, hydroxyl, amide, C1-C5 straight chain or branched alkoxy; R4 is selected from C1-C5 straight chain or branched alkylene, carbonyl, amide, halogenated C1-C5 straight chain or branched alkylene.

[0017] In a preferred embodiment, R5 is selected from hydroxy, halogen, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl, carboxyl, ester R4 is selected from methylene, ethylene, n-propylene, 2-propylene, n-butylene, isobutylene, tert-butylene, pentylene, isopentylene, tert-pentylene, halogenated methylene, halogenated ethylene, halogenated n-propylene, halogenated 2-propylene, halogenated n-butylene, halogenated isobutylene, halogenated tert-butylene, halogenated pentylene, halogenated isopentylene, halogenated tert-pentylene.

[0018] In one preferred embodiment, R1 is H, methyl, ethyl, haloethyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl.

[0019] In one preferred embodiment, R2 is selected from hydroxyl, C1-C5 alkoxy, halogen, C1-C5 alkyl; the number of R2 is 1-4, and any substitution is at positions 1-4.

[0020] In one preferred embodiment, R2 is selected from methoxy, ethoxy, propoxy, butoxy; the number of R2 is 1-4, and any substitution is at positions 1-4.

[0021] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0022]

[0023]

[0024] R1 is selected from hydrogen, C1-C8 straight or branched alkyl, C3-C8 cycloalkyl, aryl, substituted aryl, substituted C1-C8 straight or branched alkyl, substituted C3-C8 cycloalkyl; the substituents on substituted aryl, substituted C1-C8 straight or branched alkyl and substituted C3-C8 cycloalkyl are selected from halogen, amino, nitro, carboxyl, phenyl, benzyl, =O, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy;

[0025] R3 is selected from hydrogen, C1-C8 alkanoyloxy, C1-C8 alkyl.

[0026] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0027]

[0028] R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halomethyl, haloethyl, halo-n-propyl, halo-2-propyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halopentyl, halo-isopentyl, halo-tert-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and substituted phenyl;

[0029] The number of substituents on the substituted phenyl group is 1-6, and the substituents are selected from halogen, amino, nitro, carboxyl, phenyl, benzyl, =O, haloalkyl, C1-C5 straight chain or branched alkyl, halogenated C1-C5 straight chain or branched alkyl, alkenyl, alkynyl, hydroxyl, C1-C5 straight chain or branched alkoxy, C1-C5 straight chain or branched alkylene, carbonyl, halogenated C1-C5 straight chain or branched alkylene;

[0030] R3 is selected from hydrogen, C1-C8 alkanoyloxy, C1-C8 alkyl.

[0031] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0032]

[0033] R1 is H, methyl, ethyl, haloethyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl;

[0034] R3 is selected from hydrogen, C1-C8 alkanoyloxy, C1-C8 alkyl.

[0035] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0036]

[0037] R1 is H, methyl, ethyl, haloethyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl;

[0038] R3 is selected from H, C1-C8 alkanoyloxy, C1-C5 alkyl.

[0039] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0040]

[0041] R1 is H, methyl, ethyl, haloethyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl;

[0042] R3 is selected from H, C1-C8 alkanoyloxy, C1-C5 alkyl.

[0043] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0044]

[0045] R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halomethyl, haloethyl, halo-n-propyl, halo-2-propyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halopentyl, halo-isopentyl, halo-tert-pentyl, and substituted phenyl;

[0046] The number of substituents on the substituted phenyl group is 1-5, and the substituents are selected from methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, and halogenated tert-pentyl;

[0047] R3 is selected from hydrogen, C1-C8 alkanoyloxy, C1-C5 alkyl.

[0048] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0049]

[0050] R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halomethyl, haloethyl, halo-n-propyl, halo-2-propyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halopentyl, halo-isopentyl, halo-tert-pentyl, and substituted phenyl;

[0051] The number of substituents on the substituted phenyl group is 1, the position of the substituent is para or ortho, and the substituent is selected from methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, and halogenated tert-pentyl;

[0052] R3 is selected from hydrogen, C1-C8 alkanoyloxy, C1-C5 alkyl.

[0053] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0054]

[0055] R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halomethyl, haloethyl, halo-n-propyl, halo-2-propyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halopentyl, halo-isopentyl, halo-tert-pentyl, and substituted phenyl;

[0056] The number of substituents on the substituted phenyl group is 1, the position of the substituent is para or ortho, and the substituent is selected from methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, and halogenated tert-pentyl;

[0057] R3 is selected from hydrogen, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl.

[0058] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0059]

[0060] R1 is H, methyl, ethyl, haloethyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl;

[0061] R3 is selected from hydrogen, C1-C8 alkanoyloxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl.

[0062] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0063]

[0064] R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halomethyl, haloethyl, halo-n-propyl, halo-2-propyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halopentyl, halo-isopentyl, halo-tert-pentyl, and substituted phenyl;

[0065] The number of substituents on the substituted phenyl group is 1-6, and the substituents are selected from methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl, methylene, ethylene, n-propylene, 2-propylene, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methylene, halogenated ethyl, halogenated n-propylene, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl,

[0066] In one preferred embodiment, the structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows:

[0067]

[0068] R1 is H, methyl, ethyl, haloethyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl.

[0069] The present invention also claims a 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivative, the structural formula of which is shown below:

[0070]

[0071] wherein X is selected from oxygen or sulfur atoms;

[0072] R10 and R11 are independently selected from H, C1-C8 alkyl, amine, and amine-substituted C1-C8 alkyl;

[0073] R12 is selected from hydrogen, C1-C8 straight or branched alkyl, C3-C8 cycloalkyl, amine, aminealkyl, aryl, substituted aryl, substituted C1-C8 straight or branched alkyl, substituted C3-C8 cycloalkyl; the substituents on the substituted aryl, substituted C1-C8 straight or branched alkyl and substituted C3-C8 cycloalkyl are selected from halogen, amino, amine, nitro, carboxyl, phenyl, benzyl, =O, halogenated C1-C8 straight or branched alkyl, C1-C8 straight or branched alkyl, alkenyl, alkynyl, hydroxyl, alkoxy; the number of substituents on the substituted aromatic heterocycle and substituted aryl is 1-5, and any substitution is at positions 1-5.

[0074] In one preferred embodiment, each substituent on the substituted aromatic heterocycle and the substituted aromatic group is independently selected from the group consisting of methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl, methyl formate, ethyl formate, propyl formate, butyl formate, pentyl formate, and hexyl formate;

[0075] In one preferred embodiment, the C3-C8 cycloalkyl group is: furanyl, thienyl, pyrrolyl, pyrazolyl, triazolyl, thiazolyl, pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, pyridinyl, imidazolyl, 3-phenylpyrrolyl, thiazolyl-oxazolyl, tetrazolyl, isoxazolyl, indazolyl, pyridazinyl, quinolyl, purinyl, carbazolyl, acridinyl, pyrimidinyl, 2,3'-bifuranyl, imidazole, oxazole, isoxazole, thiadiazole, oxadiazole, tetrazole, pyridazine, isoquinoline or isoquinolyl.

[0076] In one preferred embodiment, the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is a compound shown in the following structure or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof:

[0077] In one preferred embodiment, the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is a compound shown in the following structure or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof:

[0078]

[0079]

[0080] The present invention also claims a method for preparing the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative.

[0081] The method comprises the following steps, when the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is a compound represented by the general formula (IV):

[0082] S1, raw material 4 undergoes substitution reaction under the action of acetic anhydride and sodium hydroxide, and then undergoes oxidation reaction under the action of hydrochloric acid and potassium dichromate to generate intermediate 5;

[0083] S2, raw material 3 and hippuric acid react under the action of sodium acetate and acetic anhydride as solvent to obtain intermediate 6;

[0084] S3, intermediate 5 and intermediate 6 undergo a ring-closing reaction to obtain the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative;

[0085] The structural formulas of the raw materials and intermediates are as follows:

[0086]

[0087] The method for preparing the 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivative, when the 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivative is a compound represented by the general formula (V), comprises the following steps:

[0088] S1, raw material 4 undergoes substitution reaction under the action of acetic anhydride and sodium hydroxide, and then undergoes oxidation reaction under the action of hydrochloric acid and potassium dichromate to generate intermediate 5;

[0089] S2, raw material 5 and chlorocarbonylsulfenyl chloride with toluene as solvent to obtain intermediate 7;

[0090] S3, intermediate 5 and intermediate 7 undergo a ring-closing reaction to obtain the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative;

[0091] The structural formulas of the raw materials and intermediates are as follows:

[0092]

[0093] The present invention also claims to protect the use of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative in the preparation of anti-psoriasis drugs.

[0094] The present invention also claims to protect the use of the 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivative in the preparation of anti-tumor drugs.

[0095] In one preferred embodiment, the tumor includes non-small cell lung cancer, breast cancer, liver cancer, and colorectal cancer.

[0096] The 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives of the present invention have significant HaCaT proliferation inhibition activity, and the cell activity of some compounds is more than 10 times higher than that of the positive control, and the IC50 even reaches the nanomolar level. It can also significantly downregulate the p-STAT3 level, inhibit the activation process of STAT3 in a dose-dependent manner, and the inhibitory ability is better than the reference substance STA21. The evaluation was conducted through the imiquimod-induced mouse psoriasis model, and the results showed that the effect of the 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives of the present invention to be tested was significantly better than Anthralin cream, and it can reduce the production of IL-17A and IL-17F. BRIEF DESCRIPTION OF THE DRAWINGS

[0097] Figure 1 The effect of the target compound on the phosphorylation process of STAT3 at different concentrations;

[0098] Figure 2 The results of the target compound's anti-psoriasis experiment in mice;

[0099] Figure 3 The experimental results show that the target compound inhibits the production of proinflammatory factors IL-17A and IL-17F. DETAILED DESCRIPTION

[0100] The invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0101] Example 1

[0102] The chemical structural formula of the present invention is the chemical structure described in Table 1 and Table 2:

[0103] Table 1 Chemical structures of A1-A20

[0104]

[0105]

[0106]

[0107] Table 2 Chemical structures of B1-B35

[0108]

[0109]

[0110] The preparation methods of the above compounds refer to the prior art: Liu Suyou, Liu Lijun, Ma Dayou, et al. Naphtho[2,3-b]isoxazole-4,9-dione derivatives and preparation methods and uses. CN201810985272.X[2024-07-01].

[0111] HaCaT cell activity was used as an in vitro model to evaluate anti-psoriatic arthritis.

[0112] The inhibitory activity of the naphtho[2,3-b]isothiazole-4,9-dione derivatives on HaCaT cells was determined by MTT method. The specific experimental process is as follows: HaCaT cells in logarithmic phase were collected, plated to adjust the density of the cells to be tested to 3000 per well, incubated at 37°C for 12 hours in 5% carbon dioxide, and then the drugs with concentration gradients were added (5 concentrations were measured for each compound). After further incubation for 48 hours, 20 μL of MTT solution (5 mg / mL) was added to each well, and the culture was continued for 4 hours. The culture medium in the well was aspirated, and 100 μL of dimethyl sulfoxide was added to each well. The absorbance value (OD value) of each well was measured at 570 nm in an enzyme-linked immunosorbent assay, and the IC value of the compound was calculated. 50 Anthralin (anthralin, an anti-psoriasis drug) was selected as a control, and the results are shown in Tables 3 and 4.

[0113] Table 3 Compounds A1-A20 inhibit HaCaT cell activity

[0114]

[0115]

[0116] Table 4 Compounds B1-B35 inhibit HaCaT cell activity

[0117]

[0118]

[0119]

[0120] As can be seen from the table, the naphtho[2,3-b]isothiazole-4,9-dione derivatives of the present invention have significant HaCaT proliferation inhibition activity, and the cell activity of some compounds is more than 10 times higher than that of the positive control. 50 Even reaching Namor level.

[0121] Example 2

[0122] The damage of target compounds to cell membrane, i.e. cytotoxicity, was evaluated by measuring LDH release activity.

[0123] HaCaT cells with good cell size and growth rate were selected and inoculated into 96-well cell culture plates. After 12 hours, IC 50 The culture medium dilution of the target compound greater than 1 μM was placed in an incubator (37°C, 5% CO2) and incubated for 4 hours. One hour before the scheduled detection time point, the LDH release reagent provided by the lactate dehydrogenase cytotoxicity kit (Shanghai Biyuntian Biotechnology Co., Ltd., product number C0017) was added to the "sample maximum enzyme activity control well". After the scheduled time, 120 μL of the supernatant from each well was taken and added to the corresponding wells of a new 96-well plate. 60 μL of LDH detection working solution was added to each well, mixed, incubated at room temperature in the dark for 30 minutes, and then the absorbance was measured at 490 nm. The results are shown in Table 5.

[0124] Table 5 Damage ability of some compounds to HaCaT cells

[0125]

[0126] The results showed that B20 caused minimal damage to cell membranes and had lower toxicity.

[0127] Example 3

[0128] Western blot experiments were performed to determine the effects of representative target compounds at different concentrations on the STAT3 phosphorylation process.

[0129] HaCaT cells with good growth status were selected, diluted at a cell density of 250,000 cells / mL, and the cell-containing culture medium was added to a 6-well plate. After incubation for 12 hours, the drug was diluted with the culture medium to the concentration gradient required for the experiment (the drug concentration of B20 was 0 / 0.25 / 0.5 / 1.0 μM), the culture medium in the 6-well plate was aspirated, and the drug culture medium dilution was added. After incubation for 24 hours, the sample protein was extracted, SDS-PAGE gel was prepared, 25 μg protein was added to each well, 100V electrophoresis was performed for 90 minutes, and then the membrane was transferred with NC membrane at 100V for 90 minutes, the target band was cut out, p-STAT3 was blocked with 5% BSA at room temperature for 1.5 hours, STAT3 and GAPDH were blocked with 5% skim milk powder at room temperature for 1.5 hours, and then the corresponding antibodies were added, incubated at 4°C overnight, the primary antibody was discarded overnight, washed three times with PBST, each time for 10 minutes, and incubated with secondary antibodies for 1.5 hours, and then washed three times with PBST, each time for 10 minutes, and developed for detection. STA21 (a STAT 3 inhibitor, 15.0 μM) and Anthralin (anthralin, 3.0 μM) were selected as controls. Figure 1As shown (only compound B20 is shown, other compounds also have obvious inhibitory effects), the experimental results prove that the naphtho[2,3-b]isoxazole-4,9-dione derivatives of the present invention can significantly downregulate the level of p-STAT3, inhibit the activation process of STAT3 in a dose-dependent manner, and the inhibitory ability of high concentration is better than that of the reference substance STA21. Specifically for compound B20, the inhibitory ability of 0.5 and 1.0 μM compound B20 is better than that of the reference substance STA21.

[0130] Example 4

[0131] The representative compound B20 was selected for animal experiments to verify its effect.

[0132] Forty BALB / C mice (Hunan Slake Jingda Experimental Animal Co., Ltd.) were randomly divided into four groups: a blank control group (vaseline), a model group (5% imiquimod cream), a positive control group (5% imiquimod cream + a gel containing 2% anthralin) and a test drug group (5% imiquimod cream + a gel containing 1% compound B20), with 10 mice in each group. One day before the experiment, the hair on the back of the mice was shaved with a shaver, and then the hair on the back of the mice was removed with a depilatory agent, with an area of ​​about 2 cm×3 cm. After the experiment started, 5% imiquimod cream was applied to the shaved part of the back of the mice at 9 am every day (the blank group was applied with the same dose of vaseline), and 2% anthralin gel (carbomer as a base 100 mg, glycerol 500 mg, sodium hydroxide 40 mg, ethanol 500 mg, distilled water added to 10000 mg, etc., was applied at 9 pm as a positive control and gel containing 1% B20 (carbomer as a base 100 mg, glycerol 500 mg, sodium hydroxide 40 mg, ethanol 500 mg, distilled water added to 10000 mg, etc., was added to make a drug gel, and then made into a 1% B20 gel) as a drug group or vaseline (blank control group) for 7 consecutive days. During the experiment, the changes in skin lesions of each group of mice were recorded daily. 24 hours after the last administration, the modeling and skin lesion changes of each group of mice were observed and the PS skin lesion area and severity index (PASI) was scored. The changes in the spleen of mice were observed, and the skin, heart, liver, spleen, lung and kidney of mice were taken for HE staining. After the psoriasis model of mice (model group) was induced by imiquimod, the skin of the mice in the model group showed typical erythema and scaling, and the lesions were thickened and psoriasis-like lesions, indicating that the modeling was successful. Then, the mice were treated with anthralin (gel containing 2% anthralin, positive control)) and B20 (gel containing 1% B20) respectively, and their effects were evaluated.

[0133] like Figure 2As shown in A-2B, compared with the control group, the skin of the mice in the model group showed typical erythema and scaling, thickened lesions, and psoriasis-like lesions. The symptoms of the treatment group were significantly alleviated compared with the model group. Figure 2 In C-2G, the PASI score showed that B20 could significantly improve the skin lesions of mice. Figure 2 H shows that the spleen of mice treated with B20 was significantly reduced, indicating that B20 can improve the inflammation induced by IMQ. In summary, compared with the positive control drug 2% anthralin, 1% B20 gel has a better therapeutic effect.

[0134] Example 5

[0135] Blood was drawn from the above model animals to measure inflammatory factors associated with the formation of psoriasis.

[0136] Blood was collected from four groups of mice: blank control group, model group (5% imiquimod cream), positive control group (5% imiquimod cream + gel containing 2% anthralin) and test drug group (5% imiquimod cream + gel containing 1% compound B20), centrifuged at 800 rpm for 20 min at 4°C, and the upper serum was drawn after centrifugation. ELISA analysis was performed according to the method of Solebao's mouse IL-17A ELISA kit. IL-17 is an inflammatory factor related to STAT3. The results of the ELISA experiment are shown in Figure 3 , respectively Figure 3 A and Figure 3 As shown in Figure B, the experimental results show that the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivatives of the present invention can significantly reduce the production of IL-17A and IL-17F.

[0137] In summary, the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivatives of the present invention have significant HaCaT proliferation inhibition activity, and the cell activity of some compounds is more than 10 times higher than that of the positive control. 50 Even reaching the nanomolar level. And it can significantly downregulate the level of p-STAT3, inhibit the activation process of STAT3 in a dose-dependent manner, and its inhibitory ability is better than that of the reference substance STA21. Through the evaluation of the imiquimod-induced mouse psoriasis model, it was found that the effect of the 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivatives of the present invention to be tested was significantly better than that of Anthralin cream, and it can reduce the production of IL-17A and IL-17F.

[0138] Example 6

[0139] Preparation of Quinoline-2,5,8(1H)-trione (Intermediate 5)

[0140]

[0141] 1000mg (6.9mmol) 8-hydroxyquinoline was dissolved in 20mL acetonitrile, 1725mg (10mmol) mCPBA was added, and the reaction was carried out at room temperature for 12h. After TLC monitoring, the reaction was complete, 20mL water was added, and 10ml 1M NaOH solution was added to adjust the pH. The solid was precipitated, filtered, and dried to obtain 1096mg bright yellow solid intermediate 5-1, with a yield of 98.7%. mp137.6-138.1℃.

[0142] 1000mg (6.21mmol) of intermediate 5-1 was dissolved in 10mL of acetic anhydride and reacted at 60℃ for 8h. After TLC monitoring, the reaction was complete. 100ml of 1M NaOH solution was added and allowed to stand at 0℃ for a period of time to obtain a solid precipitate. After suction filtration and drying, 1225mg of khaki solid intermediate 5-2 was obtained. The yield was 97.1%. mp 252.6-253.7℃.

[0143] 1000mg (4.93mmol) of compound intermediate 5-2 was added with 10ml 8M hydrochloric acid solution, and the reaction was carried out at 90℃ for 1h. After TLC monitoring, the reaction was complete, and the precipitated solid was filtered and dried to obtain 785mg of gray solid intermediate 5-3, with a yield of 98.9%. mp 298.3-299.2℃.

[0144] 1000mg (6.21mmol) of compound intermediate 5-3 was dissolved in 10mL DCM, 20ml of 2M sulfuric acid solution was added, 1883mg (6.4mmol) of potassium dichromate was added, and the mixture was reacted at 0°C for 1h. The organic layer was monitored by TLC. After the reaction was complete, 100mL of water was added, and DCM was extracted 3 times (30mL×3). The organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was removed by reduced pressure distillation using a rotary evaporator to obtain 423mg of a solid crude product. The crude product was recrystallized with 10ml of EA to obtain 315mg of an orange-yellow solid intermediate 5 with a yield of 30.0%. 1 HNMR (500MHz, CDCl3) δ10.03 (s, 1H), 7.98 (d, J = 9.5Hz, 1H), 7.01-6.87 (m, 3H).

[0145] Example 7

[0146] Preparation of 3-methylisothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 24) and 3-methylisothiazo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 30)

[0147]

[0148] 177 mg (3 mmol) of acetamide raw material 5 was dissolved in 8 mL of toluene, 252 μL (2 mmol) of chlorocarbonyl sulfonyl chloride was added, and the reaction was carried out at 100°C for 3 h. After TLC monitoring, the reaction was completed, cooled to room temperature, and the solvent was removed by vacuum distillation using a rotary evaporator. 20 mL of water was added, and EA was extracted 3 times (15 mL × 3). The organic layers were combined and dried over anhydrous Na2SO4. The solvent was removed by vacuum distillation using a rotary evaporator to obtain 200 mg of colorless oil intermediate 6-1, with a yield of 57.0%. The crude product was directly used for the next step without further purification.

[0149] 175 mg (1 mmol) of intermediate 5 was dissolved in 5 mL of xylene, and 117 mg (1 mmol) of compound intermediate 6-1 was added. The reaction was refluxed for 12 h under nitrogen protection. The reaction was complete after TLC monitoring. The organic phase was extracted with EA 3 times (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate, concentrated and mixed, and purified on a 200-300 mesh silica gel column. The eluent was a DCM / EA mixed solution system [V (DCM) ∶ V (EA) = 30 ∶ 1] to obtain 26 mg of yellow solid 24 with a yield of 10.6%; 19 mg of orange solid 30 with a yield of 7.7%. Compound 24: 1 H NMR (500MHz, DMSO-d6) δ12.41(s,1H),7.97(d,J=9.2Hz,1H),6.75(d,J=9.3Hz,1H),2.72(s,3H). 13 C NMR(126MHz,DMSO-d6)δ177.62(s),176.95(s),173.05(s),168.83(s),168.35(s) ,150.86(s),134.02(s),130.60(s),129.70(s),128.50(s),22.18(s).ESI-HR-MS m / z[M+H] + Calculate for C 11 H7N2O3S, 246.0099; found, 246.0101. Compound 30: 1 H NMR (500MHz, DMSO-d6) δ12.28 (s, 1H), 7.73 (d, J = 7.0Hz, 2H), 7.57-7.47 (m, 3H), 6.69 (s, 1H), 2.51 (s, 3H). 13C NMR(126MHz,DMSO-d6)δ177.80(s),173.00(s),168.39(s),165.75(s),163.10(s) ,143.21(s),136.50(s),132.45(s),125.41(s),117.22(s),19.77(s).ESI-HR-MS m / z[M+H] + Calculate for C 11 H7N2O3S,246.0099; found,246.0099.

[0150] Example 8

[0151] Preparation of 3-ethylisothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 25) and 3-ethylisothiazo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 31)

[0152]

[0153] The synthetic method of reference example 7 was used to obtain a yellow solid (Compound 25) with a yield of 10.8%. An orange solid 31 was obtained with a yield of 8.1%. Compound 25: 1 H NMR (500MHz, DMSO-d6) δ12.42(s,1H),7.98(d,J=9.4Hz,1H),6.75(d,J=9.4Hz,1H),3.14(q,J=7.3Hz,2H),1.29(t,J=7.3Hz,3H). 13 C NMR(126MHz,DMSO-d6)δ175.24(s),174.16(s),173.19(s),165.46(s),162.72(s),143 .14(s),135.86(s),131.78(s),125.33(s),115.55(s),26.59(s),12.20(s).ESI-HR-MS m / z[M+H] + Calculate for C 12 H9N2O3S, 260.0256; found, 260.0259. Compound 31: 1 H NMR (500MHz, DMSO-d6) δ12.49(s,1H),8.05(d,J=8.6Hz,1H),6.83(d,J=8.9Hz,1H),3.18(q,J=7.4Hz,2H),1.29(t,J=7.4Hz,3H). 13C NMR(126MHz,DMSO-d6)δ180.57(s),173.24(s),168.78(s),164.23(s),159.11(s),141.86( s),138.43(s),132.00(s),128.11(s),117.27(s),26.62(s),12.39(s).ESI-HR-MSm / z[M+H] + Calculate for C 12 H9N2O3S,260.0256; found,260.0259.

[0154] Example 9

[0155] Preparation of 3-phenylisothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 26) and 3-phenylisothiazo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 32)

[0156]

[0157] Referring to the synthesis method of Example 7, yellow solid 26 was obtained with a yield of 20.1% and orange solid 32 with a yield of 11.4%. Compound 26: 1 H NMR (500MHz, DMSO-d6) δ12.18(s,1H),8.01(d,J=9.5Hz,1H),7.80(d,J=7.2Hz,2H),7.60-7.47(m,3H),6.77(d,J=9.5Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ175.15(s),173.25(s),168.72(s),166.89(s),162.51(s),143.56(s),135. 61(s),134.11(s),131.74(s),130.51(s),129.71(s),128.41(s),125.50(s),115.13(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H8N2O3S, 308.0256; found, 308.0260. Compound 32: 1 HNMR (500MHz, DMSO-d6) δ12.52(s,1H),8.03(s,1H),7.76(d,J=7.4Hz,2H),7.59-7.47(m,3H),6.86(s,1H). 13CNMR(126MHz,DMSO-d6)δ174.58(s),172.56(s),167.92(s),162.76(s),134.31(s),130.40(s),129.85(s),128.37(s),126.60(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H8N2O3S,308.0256; found,308.0260.

[0158] Example 10

[0159] Preparation of the Synthesis of 3-(1-morpholinyl)isothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 27)

[0160]

[0161] Referring to the synthesis method of Example 7, a purple solid 27 was obtained with a yield of 30.0%. Compound 27: 1 H NMR (500MHz, DMSO-d6) δ12.29(s,1H),7.97(d,J=9.6Hz,1H),6.72(d,J=9.1Hz,1H),3.77(s,4H),3.42(s,4H). 13 C NMR (126MHz, DMSO-d6) δ175.29(s), 172.30(s), 167.34(d, J=10.3Hz), 162.51(s), 143.70(s) ),135.55(s),125.24(s),123.80(s),114.51(s),66.22(s),55.41(s),49.97(s).ESI-HR-MS m / z[M+H] + Calculate for C 14 H 11 N3O4S,317.0470; found,317.0474.

[0162] Embodiment 11

[0163] Preparation of the Synthesis of 3-(1-piperidinyl)isothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 28)

[0164]

[0165] Referring to the synthesis method of Example 7, a purple solid 28 was obtained with a yield of 27.9%. Compound 28: 1H NMR (500MHz, DMSO-d6) δ12.24(s,1H),7.96(d,J=9.3Hz,1H),6.71(d,J=9.4Hz,1H),3.38(s,4H),1.68(s,4H)),1.62(s,2H). 13 C NMR(126MHz,DMSO-d6)δ175.35(s),172.19(s),171.73(s),167.95(s),167.16(s),135.54(s) ),125.08(s),123.67(s),121.01(s),117.98(s),50.72(s),25.66(s),24.17(s).ESI-HR-MS m / z[M+H] + Calculate for C 15 H 13 N3O3S,315.0678; found,315.0682.

[0166] Example 12

[0167] Preparation of the Synthesis of 3-(1-pyrrolyl)isothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 29)

[0168]

[0169] Referring to the synthesis method of Example 7, a purple solid 29 was obtained with a yield of 29.6%. Compound 29: 1 H NMR (500MHz, DMSO-d6) δ12.24(s,1H),7.96(d,J=9.5Hz,1H),6.71(d,J=9.5Hz,1H),3.59(s,4H),1.92(s,4H). 13 C NMR(126MHz,DMSO-d6)δ175.18(s),164.60(s),137.50(s),135.59(s),129.15(s),121.74(s),51.01(s),25.68(s).ESI-HR-MS m / z[M+H] + Calculate for C 14 H 11 N3O3S,301.0521; found,301.0521.

[0170] Embodiment 13

[0171] Preparation of 8-methyl-3-phenylisothiazo[5,4g]quinoline-4,6,9[5H]-trione (Compound 33) and 8-methyl-3-phenylisothiazo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 34)

[0172]

[0173] Referring to the synthesis method of Example 7, yellow solid 33 was obtained with a yield of 13.4% and orange solid 34 with a yield of 8.1%. Compound 33: 1 H NMR (500MHz, DMSO-d6) δ12.11 (s, 1H), 7.82 (d, J = 7.2Hz, 2H), 7.61-7.44 (m, 3H), 6.59 (s, 1H), 2.56 (s, 3H). 13 C NMR(126MHz,DMSO-d6)δ176.95(s),173.05(s),168.83(s),168.35(s),150.88(s) ,134.02(s),130.79(s),130.60(s),129.70(s),128.50(s),22.18(s).ESI-HR-MS m / z[M+H] + Calculate for C 17 H 12 N2O3S, 322.0412; found, 322.0415. Compound 34: 1 H NMR (500MHz, DMSO-d6) δ12.27(s,1H),7.73(d,J=7.0Hz,2H),7.52(q,J=6.4Hz,3H),6.69(s,1H),2.51(s,3H). 13 C NMR(126MHz, DMSO-d6)δ178.73(d,J=4.2Hz),169.02(s),134.63(s),133.45(s),130.21(s),129.79(s),128.37(s),22.64(s).ESI-HR-MS m / z[M+H] + Calculate for C 17 H 10 N2O3S,322.0412; found,322.0417.

[0174] Embodiment 14

[0175] Preparation of the Synthesis of 3-phenylisoxazole [4,5-g] quinoline-4,7,9 [8H] -trione (Compound 35) and 3-phenylisoxazole [5,4g] quinoline-4,6,9 [5H] -trione (Compound 42)

[0176]

[0177] 1000mg (5.59mmol) hippuric acid was dissolved in 5mL acetic anhydride, 815μL (8mmol) benzaldehyde raw material 3 was added, 328mg (4mmol) sodium acetate was added, and the reaction was carried out at 140℃ for 4h. The organic layer was monitored by TLC. The reaction was complete. After cooling to room temperature, a yellow solid was precipitated, filtered, rinsed with a small amount of EA, and dried at 50℃. The crude product was recrystallized with 10ml EA to obtain 837mg yellow solid, with a yield of 60.1%. Intermediate 6-1: 1 H NMR (400MHz, CDCl3) δ8.23(td,J=8.5,1.7Hz,4H),7.65(t,J=7.4Hz,1H),7.57(t,J=7.5Hz,2H),7.54-7.47(m,3H),7.29(s,1H).

[0178] 263 mg (1.5 mmol) of intermediate 5 was dissolved in 5 mL of 1,4-dioxane, and 249 mg (1 mmol) of intermediate 6-1 was added, and 484 mg (2 mmol) of copper nitrate trihydrate and 166 mg (1 mmol) of potassium iodide were added. The mixture was refluxed at 80°C for 3 h. After TLC monitoring, the reaction was complete. The solvent was dried, 40 mL of water was added, and EA was extracted 3 times (15 mL×3). The organic phase was dried over anhydrous sodium sulfate, concentrated and mixed, and purified on a 200-300 mesh silica gel column. The eluent was a DCM / EA mixed solution system [V(DCM)∶V(EA)=30∶1], and 29 mg of yellow solid 35 was obtained, with a yield of 9.9%; 48 mg of orange solid 42, with a yield of 16.4%. Compound 35: 1 H NMR (500MHz, DMSO-d6) δ12.67(s,1H),8.07(t,J=11.1Hz,3H),7.66-7.57(m,3H),6.88(d,J=7.2Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ177.15(s),169.22(s),166.41(s),160.52(s),136.76(s),131.84(s),129.62-129.16(m),126.34(s),117.60(s).ESI-HR-MS m / z[M+H] + Calculate for C 16H8N2O4, 292.0484; found, 292.0490. Compound 42: 1 H NMR (500MHz, DMSO-d6) δ12.52(s,1H),8.04(t,J=8.7Hz,3H),7.64(dt,J=14.2,7.1Hz,3H),6.80(d,J=9.4Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ174.09(s),171.35(s),167.96(s),166.36(s),160.36(s),143.54(s),140. 35(s),135.67(s),134.34(s),131.97(s),129.39(s),126.21(s),122.30(s),117.59(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H8N2O4,292.0484; found,292.0489.

[0179] Embodiment 15

[0180] Preparation of the Synthesis of 3-(4-fluorophenyl)isoxazolo[5,4g]quinoline-4,6,9[5H]-trione (Compound 36) and 3-(4-fluorophenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 43)

[0181]

[0182] Referring to the synthesis method of Example 14, a light yellow solid 36 was obtained with a yield of 6.8%; a dark yellow solid 43 was obtained with a yield of 11.3%. Compound 36: 1 H NMR (500MHz, DMSO-d6) δ12.60(s,1H),8.14(s,3H),7.43(s,2H),6.89(s,1H). 13 C NMR(126MHz,DMSO-d6)δ177.29(s),166.43(s),165.33(s),163.36(s),159.57(s) ,136.79(s),132.11(s),122.87(s),117.50(s),116.53(s),116.35(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7FN2O4,310.0390; found,310.0392. Compound 43:

[0183] 1 H NMR (500MHz, DMSO-d6) δ12.53(s,1H),8.12(dd,J=8.5,5.5Hz,2H),8.06(d,J=9.4Hz,1H),7.49(t,J=8.8Hz,2H),6.81(d,J=9.4Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ171.31(s),166.32(s),165.40(s),163.42(s),159.47(s),135.69(s) ,131.96(d,J=9.0Hz),124.36-122.88(m),122.72(d,J=3.2Hz),124.36-116.81(m).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7FN2O4,310.0390; found,310.0393.

[0184] Example 16

[0185] Preparation of 3-(4-bromophenyl)isoxazolo[5,4g]quinoline-4,6,9[5H]-trione (Compound 37) and 3-(4-bromophenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 45)

[0186]

[0187] Referring to the synthesis method of Example 14, yellow solid 37 was obtained with a yield of 10.0% and orange solid 45 with a yield of 14.9%. Compound 37: 1 H NMR (500MHz, DMSO-d6) δ12.53(s,1H),8.05(d,J=9.4Hz,1H),8.00(d,J=8.4Hz,2H),7.86(d,J=8.4Hz,2H),6.81(d,J=9.4Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ174.13(s),171.25(s),166.37(s),162.77(s),159.53(s),143.47(s),135. 69(s),132.50(s),131.33(s),125.77(s),125.43(s),120.64(s),117.62(s),114.74(s).ESI-HR-MS m / z[M+H] + Calculate for C16 H7BrN2O4, 369.9589; found, 369.9592. Compound 45: 1 HNMR (500MHz, DMSO-d6) δ12.68(s,1H),8.08(d,J=7.4Hz,1H),8.03(d,J=8.3Hz,2H),7.82(d,J=8.3Hz,2H),6.87(d,J=9.1Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ177.14(s),166.49(s),159.68(s),136.77(s),132.90(s) ,132.40(s),131.49(s),130.64(s),125.60(d,J=10.2Hz),117.57(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7BrN2O4,369.9596; found,369.9589.

[0188] Embodiment 17

[0189] Preparation of 3-(3-bromophenyl)isoxazolo[5,4g]quinoline-4,6,9[5H]-trione (Compound 38) and 3-(3-bromophenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 46)

[0190]

[0191] Referring to the synthesis method of Example 14, yellow solid 38 was obtained with a yield of 6.2% and orange solid 46 with a yield of 9.5%. Compound 38: 1 H NMR (500MHz, DMSO-d6) δ12.55(s,1H),8.27(s,1H),8.04(t,J=7.8Hz,2H),7.87(d,J=8.1Hz,1H),7.59(t,J=7.9Hz,1H),6.81(d,J=9.5Hz,1H). 13C NMR(126MHz,DMSO-d6)δ174.12(s),171.20(s),166.29(s),162.70(s),159.10(s),143.62(s),135.63(s),134. 77(s),131.99(s),131.61(s),128.35(s),128.19(s),125.15(s),122.39(s),117.68(s),114.59(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7BrN2O4, 369.9589; found, 369.9591. Compound 46: 1 H NMR (500MHz, DMSO-d6) δ12.70(s,1H),8.32(s,1H),8.12(s,1H),8.07(d,J=7.8Hz,1H),7.86(d,J=8.7Hz,1H),7.58(t,J=7.9Hz,1H),6.89(s,1H). 13 CNMR(126MHz,DMSO-d6)δ177.17(s),171.54(s),166.44(s),163.64(s),159.25(s),136.80(s),134. 65(s),132.09(s),131.53(s),128.52(s),128.39(s),127.62(s),122.32(s),117.66(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7BrN2O4,369.9589; found,369.9591.

[0192] Embodiment 18

[0193] Preparation of 3-(2-bromophenyl)isoxazolo[5,4g]quinoline-4,6,9[5H]-trione (Compound 39) and 3-(2-bromophenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 47)

[0194]

[0195] Referring to the synthesis method of Example 14, yellow solid 39 was obtained with a yield of 5.7% and orange solid 47 with a yield of 10.3%. Compound 39: 1H NMR (500MHz, DMSO-d6) δ12.65(s,1H),7.99(s,1H),7.91-7.84(m,1H),7.62-7.53(m,3H),6.84(s,1H). 13 C NMR(101MHz,DMSO-d6)δ176.67(s),165.68(s),159.21(s),136.75(s),131. 32(s),130.39(s),129.80(s),129.46(s),125.22(s),117.05(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7BrN2O4,369.9589; found,369.9594. Compound 47: 1 HNMR (500MHz, DMSO-d6) δ12.51(s,1H),8.06(d,J=5.6Hz,1H),7.89(d,J=6.8Hz,1H),7.65-7.53(m,3H),6.81(d,J=7.7Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ173.72(s),171.26(s),165.56(s),159.64(s),155.98(s),135.78(s),133. 52(s),133.13(s),132.63(s),132.31(s),128.40(s),127.64(s),122.86(s),118.60(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7BrN2O4,369.9589; found,369.9593.

[0196] Embodiment 19

[0197] Preparation of the Synthesis of 3-(4-acetoxyphenyl)isoxazolo[5,4g]quinoline-4,6,9[5H]-trione (Compound 40) and 3-(4-acetoxyphenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 48)

[0198]

[0199] The synthetic method of reference example 14 was used to obtain yellow solid 40 with a yield of 7.1%; 53 mg of orange solid 48 was obtained with a yield of 7.1%.

[0200] The rate was 15.1%. Compound 40:1 H NMR (400MHz, DMSO-d6) δ12.51(s,1H),8.08(t,J=11.7Hz,3H),7.41(d,J=8.4Hz,2H),6.81(d,J=9.4Hz,1H),2.34(s,3H). 13 C NMR(101MHz,DMSO-d6)δ171.32(s),169.52(s),166.35(s),159.69(s),153.29(s),140 .03(s),130.83(s),123.71(s),122.95(d,J=9.5Hz),117.57(s),21.37(s).ESI-HR-MS m / z[M+H] + calcdfor C 16 H7BrN2O4, 350.0539; found, 350.0542. Compound 48: 1 H NMR (400MHz, DMSO-d6) δ12.69(s,1H),8.13(d,J=8.6Hz,3H),7.39(d,J=8.6Hz,2H),6.87(s,1H),2.34(s,3H). 13 C NMR(101MHz,DMSO-d6)δ173.29(s),169.52(s),166.49(s),158.78(s),153.22(s),130. 99(s),130.06(s),125.85(s),123.87(s),122.93(s),120.42(s),21.39(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7BrN2O4,350.0539; found,350.0542.

[0201] Embodiment 20

[0202] Preparation of 3-(4-nitrophenyl)isoxazolo[5,4g]quinoline-4,6,9[5H]-trione (Compound 41) and 3-(4-nitrophenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 51)

[0203]

[0204] Referring to the synthesis method of Example 14, yellow solid 41 was obtained with a yield of 9.5% and orange solid 51 with a yield of 16.9%. Compound 41: 1H NMR (500MHz, DMSO-d6) δ12.62(s,1H),8.48(d,J=7.9Hz,2H),8.31(d,J=8.0Hz,2H),8.08(d,J=9.1Hz,1H),6.83(d,J=9.0Hz,1H). 13 C NMR(126MHz,DMSO-d6)δ171.18(s),166.50(s),163.02(s),158.95(s),149.66(s),135.74(s) ,134.49(s),133.92(s),132.22(d,J=19.9Hz),130.89(s),129.15(s),124.50(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7N3O6,337.0335; found,337.0338. Compound 51: 1 H NMR (500MHz, DMSO-d6) δ12.71(s,1H),8.46(d,J=8.3Hz,2H),8.36(d,J=8.2Hz,2H),8.09(s,1H),6.90(s,1H). 13 CNMR(126MHz,DMSO-d6)δ151.10(s),149.60(s),132.45(s),131.05(s),124.41(s),119.31(s),116.75(s),114.25(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H7N3O6,337.0335; found,337.0339.

[0205] Embodiment 21

[0206] Preparation of the Synthesis of 3-(4-chlorophenyl)isoxazolo[4,5g]quinoline-4,6,9[5H]-trione (Compound 44)

[0207]

[0208] Referring to the synthesis method of Example 14, an orange solid 44 was obtained with a yield of 9.8%. Compound 44: 1 H NMR (400MHz, DMSO-d6) δ12.73(s,1H),8.11(d,J=8.5Hz,3H),7.70(d,J=8.6Hz,2H),6.87(d,J=9.5Hz,1H). 13C NMR(101MHz,DMSO-d6)δ176.67(s),165.68(s),159.21(s),136.75(s),131. 32(s),130.39(s),129.80(s),129.46(s),125.22(s),117.05(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H9ClN2O4,328.0254; found,328.0251.

[0209] Embodiment 22

[0210] Preparation of the Synthesis of 3-(4-Hydroxyphenyl)-3-phenylisothiazo[4,5g]quinoline-4,6,9[5H]-trione (Compound 49)

[0211]

[0212] 35 mg (0.1 mmol) of compound 48 was added to 2 ml of 2M hydrochloric acid solution, and the mixture was reacted at 90°C for 1 h. After TLC monitoring, the reaction was complete. The mixture was filtered, rinsed with EA, and dried to obtain 29 mg of a red solid with a yield of 94.2%. Compound 49: 1 HNMR(500MHz,DMSO-d6)δ12.61(s,1H),10.23(s,1H),8.08(d,J=6.6Hz,1H),7.96(d,J=8.6Hz,2H),6.96(d,J=8.6Hz,2H),6.87(s,1H).13C NMR(126MHz,DMSO-d6)δ177.35(s),169.21(s),166.29(s),160.82(s),160.31(s),136.90(s),131 .18(d,J=16.0Hz),124.94(s),117.38(s),116.81(s),116.64(s),116.06(d,J=8.9Hz).ESI-HR-MS m / z[M+H] + Calculate for C 16 H9N2O5, 308.0433; found, 308.0434.

[0213] Embodiment 23

[0214] Preparation of the Synthesis of 3-(4-acetyloxyphenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 50)

[0215]

[0216] Referring to the synthesis method of Example 31, a yellow solid was obtained with a yield of 4.9%. Compound 50: 1 H NMR (500MHz, DMSO-d6) δ8.42(d,J=8.6Hz,1H),8.14(d,J=8.6Hz,2H),7.39(d,J=8.5Hz,2H),7.30(d,J=8.6Hz,1H),4.06(s,3H),2.35(s,3H). 13 C NMR(126MHz,DMSO-d6)δ176.88(s),172.45(s),169.44(s),167.20(s),166.64(s),160.06(s),153.22(s),149.27(s) ),137.91(s),130.97(s),124.33(s),123.90(s),122.86(s),119.22(s),116.30(s),54.96(s),21.37(s).ESI-HR-MS m / z[M+H] + Calculate for C 18 H 10 N2O6,364.0695; found,364.0699.

[0217] Embodiment 24

[0218] Preparation of the Synthesis of 3-(4-aminophenyl)isoxazolo[4,5-g]quinoline-4,7,9[8H]-trione (Compound 52)

[0219]

[0220] 50 mg (0.15 mmol) of compound 51 was dissolved in 3 mL of ethanol, and 169 mg (0.75 mmol) of stannous chloride dihydrate was added. The mixture was protected by N2 and refluxed at 80°C for 3 h. After TLC monitoring, the reaction was complete. The solvent was dried by spin drying, 10 mL of 1M hydrochloric acid was added, and EA was extracted 3 times (15 mL×5). The organic phase was dried over anhydrous sodium sulfate and the solid crude product was dried by spin drying. The product was rinsed with a small amount of methanol to obtain 25 mg of purple-black solid 52. The yield was 54.3%. Compound 52: 1 H NMR (500MHz, DMSO-d6) δ12.60(s,1H),8.10(s,1H),7.86(s,2H),6.72(s,1H),6.68(d,J=8.4Hz,2H),5.83(s,2H). 13C NMR(126MHz,DMSO-d6)δ169.48(s),161.32(s),155.90(s),152.32(s),146.95(s),140.30(s),135. 14(s),127.92(s),124.21(s),120.24(s),117.78(s),113.61(s),112.60(s),111.06(s).ESI-HR-MS m / z[M+H] + Calculate for C 16 H9N3O4,307.0593; found,307.0599.

[0221] Embodiment 25

[0222] Preparation of the Synthesis of 3-(4-aminophenyl)-5-(2-morpholinoethyl)isothiazo[4,5g]quinoline-4,7,9[8H]-trione (Compound 53)

[0223]

[0224] 31 mg (0.1 mmol) of compound 52 was dissolved in 3 mL of isopropanol, 15 mg (0.1 mmol) of 4-(2-chloroethyl)morpholine and 56 mg (0.4 mmol) of potassium carbonate were added, and the reaction was carried out at 80°C for 4 h. After TLC monitoring, the reaction was complete, 20 mL of water was added, and EA was extracted 3 times (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, concentrated and mixed, and purified on a 200-300 mesh silica gel column with a DCM / EA mixed solution system [V(DCM):V(EA)=5:1] as the eluent. The black solid 53 (10 mg) was obtained by spin drying with a yield of 23.8%. Compound 53: 1 H NMR (500MHz, DMSO) δ8.38(d,J=8.6Hz,1H),7.87(d,J=8.4Hz,2H),7.31(d,J=8.6Hz,1H),6.69(d,J=8.3Hz ,2H),5.84(d,J=15.9Hz,2H),4.61(t,J=5.1Hz,2H),3.57(s,4H),3.49(s,2H),2.78(s,2H),2.45(s,2H). 13C NMR (126MHz, DMSO) δ177.99(s),171.83(s),167.20(s),166.30(s),160.67(s),152.31(s),147.36(s),138.49(s),130. 75(s),126.30(s),118.19(s),116.85(s),113.62(s),112.70(s),66.56(s),64.38(s),57.14(s),53.92(s).ESI-HR-MS m / z[M+H] + Calculate for C 22 H 20 N4O5,420.1434; found,420.1440.

[0225] Embodiment 26

[0226] Human keratinocytes (HaCaT cells), human non-small cell lung cancer cells A549, human breast cancer cells MDA-MB-231, human liver cancer cells HepG2, and human colorectal cancer cells HT-29 were used to determine the proliferation inhibitory activity of the compounds.

[0227] (1) Experimental method: a. Plating: Select HaCaT cells with good growth status, carefully remove the old culture medium, add 2mL of PBS buffer to wash the culture dish, and discard it. Add 1mL of EDTA-containing trypsin for digestion. When the cells are no longer attached to the wall, add 2mL of fresh culture medium to terminate the digestion, transfer to a 15mL centrifuge tube, and centrifuge at 800rpm in a low-speed centrifuge for 5min. Discard the supernatant, add 3mL of culture medium, blow evenly, take out 50μL of cell suspension and add it to 450μL of PBS buffer for dilution, use a hemocytometer to count the cells, and calculate the cell density in the cell suspension. Take the cell density as 3×10 4 / mL for dilution, after blowing evenly, add the cell-containing culture medium to a 96-well plate (100μL per well), and incubate in a cell culture incubator (37°C, 5% CO2); b. After incubation for 12h, dilute the drug with culture medium into 6 concentration gradients according to the experimental requirements, then in the biosafety cabinet, aspirate the old culture medium in the 96-well plate, add the drug culture medium dilution (100μL per well), and incubate in an incubator (37°C, 5% CO2); c. After incubation for 48h, add 20μL 5mg / mL MTT solution to each well under light-proof conditions, and then continue to incubate in a cell culture incubator; d. After incubation for 4h, carefully aspirate the liquid in the 96-well plate, add 100μL per well DMSO was shaken at low speed on a shaker for 30 seconds, and the OD value of each well at 570 nm was measured with an enzyme-labeled instrument; e. A blank group (culture medium, MTT), a control group (cells, culture medium, DMSO, MTT), and a drug group (cells, culture medium, drug, MTT) were set up in the experiment. There were 3 replicate wells at each drug concentration, and the experiment was repeated 3 times.

[0228] Relative cell survival rate = (OD value of drug group - OD value of blank group) / (OD value of control group - OD value of blank group) × 100%

[0229] The inhibition rate of the compound on cells = 100% - survival rate

[0230] Use software to process data and calculate the IC of the compound 50 value.

[0231] (2) Experimental results: The proliferation inhibitory activity of the target compounds on the human keratinocyte cell line (HaCaT) is shown in Table 5. The results show that naphthoquinone derivatives have strong inhibitory activity on the proliferation process of HaCaT cells in vitro. The activity of some compounds reaches the nanomolar level, which is significantly better than the control.

[0232] Table 5 IC inhibitory activity of target compounds on A549, MDA-MB-231, HepG2, HT-29 and HaCaT cells 50 (μM) and LDH release activity

[0233]

[0234]

[0235]

[0236]

[0237]

[0238] Embodiment 27

[0239] Select compounds for Western Blot to determine the effect of the compounds on p-STAT3 levels

[0240] (1) Experimental principle: The sample protein is separated by polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a solid phase carrier that adsorbs the protein in a non-covalent bond form. The protein or peptide on the solid phase carrier is used as the antigen, and the antibody is used as the "probe" for specific binding. The enzyme or isotope-labeled secondary antibody is then combined with the primary antibody, and the expression level of the specific target protein separated by electrophoresis is detected through substrate color development or radioautography.

[0241] (2) Experimental methods: a. Plating: Select HaCaT cells with good growth status, wash with PBS, digest with trypsin, centrifuge, discard the supernatant, add 3 mL of culture medium, blow evenly, take out 50 μL of liquid and add it to 450 μL of PBS buffer, blow evenly, count the cells with a hemocytometer, and calculate the cell density of the liquid. Then, take the cell density as 2.5×10 5 / mL for dilution, after blowing and beating evenly, add the cell-containing culture medium to the six-well plate (2mL per well), and place it in a cell culture incubator (37°C, 5% CO2) for incubation; b. Administration: After incubation for 12 hours, dilute the target compound with good cell activity with the culture medium to the concentration gradient required for the experiment, then in the biosafety cabinet, aspirate the culture medium in the six-well plate, add the drug culture medium dilution (2mL per well), and place it in an incubator (37°C, 5% CO2) for incubation. c. Preparation of sample protein: After incubation for 24 hours, transfer the six-well plate to ice, aspirate the cell culture medium, wash twice with pre-cooled PBS, add cell lysis buffer RIPA, phosphatase inhibitors and protease inhibitors, lyse for 30 minutes, scrape the cells with a pre-cooled cell scraper, centrifuge at 13800rpm for 20 minutes at 4°C, transfer the supernatant after centrifugation to a 1.5ml EP tube, and detect the protein concentration with a BCA kit. Adjust all protein samples to equal concentration, mix thoroughly, add 4× loading buffer, boil in metal bath, 100℃, 10min before loading. d. Prepare SDS-PAGE gel, load, add 20μg sample protein to each well, electrophoresis 100V, 90min. Then transfer to NC membrane, 100V, 90min, cut out the target band, block p-STAT3 with 5% BSA at room temperature for 1h, block STAT3 and GAPDH with 5% skim milk powder at room temperature for 1h, incubate with primary antibody at 4℃ overnight, wash three times with PBST, 10min each time, incubate with secondary antibody at room temperature for 1h, wash three times with PBST, 10min each time, and develop and detect.

[0242] Bound immune complexes were detected using Image Lab 4.0.1.

[0243] (3) Experimental results: Figure 1 As shown, Figure 1 The representative compounds shown can significantly downregulate the expression level of p-STAT3 in HaCaT cells, while having no significant effect on the total STAT3 protein level. The figure only shows the data results of compound 18. Therefore, the compounds of the present invention are effective STAT3 phosphorylation inhibitors.

[0244] Embodiment 28

[0245] Select compounds with good cell activity for LDH release activity assay to determine the effect of target compounds on cell membrane

[0246] (1) Experimental principle: Use the lactate dehydrogenase cytotoxicity detection kit for detection. The destruction of the cell membrane structure caused by cell apoptosis or necrosis will cause the enzymes in the cytoplasm to be released into the culture medium, including lactate dehydrogenase (LDH) with relatively stable enzyme activity. LDH release is regarded as an important indicator of cell membrane integrity. Under the action of LDH, NAD+ is reduced to NADH, and NADH and INT are catalyzed by lipoamide dehydrogenase to generate NAD+ and a strong colorant formazan, which produces an absorption peak at a wavelength of 490nm. Its absorbance is linearly positively correlated with LDH activity and can be used to quantify LDH activity.

[0247] (2) Experimental methods: a. Plating: Select HaCaT cells in good growth condition, wash with PBS, digest with trypsin, and centrifuge. Discard the supernatant and add 3 mL of culture medium. After pipetting evenly, take out 50 μL of the liquid and add it to 450 μL of PBS buffer. Pipet and pipet evenly. Count the cells using a hemacytometer and calculate the cell density of the liquid. Then dilute according to the cell density of 5×104 cells / mL, blow evenly, add to a 96-well plate (100 μL per well), and incubate in a cell culture incubator (37°C, 5% CO2); b. After incubation for 12 hours, dilute the drug to the required concentration with serum-free 1640 medium, carefully remove the old medium in the 96-well plate, add the medium dilution of the drug (150 μL per well), and incubate in a cell culture incubator (37°C, 5% CO2); c. After the drug is incubated for 3 hours, add 15 μL of LDH releaser to the maximum LDH release well, continue to incubate in a cell culture incubator (37°C, 5% CO2) for 1 hour, and prepare the detection working solution according to the instructions of the kit. d. Place the 96-well plate in a multi-well plate centrifuge and centrifuge at 800rpm for 5 minutes. Carefully draw 120μL of the upper culture medium from the old 96-well plate into the new 96-well plate, add 60μL of working solution in the dark, incubate at room temperature in the dark for 30-40 minutes, and measure the absorbance at 490nm with an ELISA reader. e. Set up a blank group (no cells, culture medium), a control group (cells, culture medium, DMSO), a maximum release well (cells, culture medium, DMSO, LDH releaser) and a drug group (cells, culture medium, drug) in the experiment, and set up 2 replicate wells at each drug concentration.

[0248] The calibration curve was drawn using the LDH standard and the corresponding absorbance values. The LDH enzyme activity of the sample was calculated based on the standard curve formula and the actual absorbance value of the sample. The data were expressed as mU.

[0249] (3) Experimental results: The LDH release activity of the target compound on human keratinocytes (HaCaT) is shown in Table 5. The LDH release activity of the quinone compounds is basically consistent with their antiproliferative activity, that is, the higher the antiproliferative activity, the more LDH is released, and the greater the cytotoxicity. Surprisingly, the antiproliferative activity of compound 18 is 26 times that of BBI608, but its LDH release activity is smaller, that is, the cytotoxicity is small, which shows that the compound of the present invention can be used as a potential candidate drug for anti-psoriasis.

Claims

1. Use of 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivatives in the preparation of anti-psoriasis drugs, characterized in that: The structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is shown in general formula (I): Wherein, X is selected from oxygen or sulfur atom; Y and Z are independently selected from carbon or nitrogen atom; R1 is selected from hydrogen, C1-C8 straight or branched alkyl, C3-C8 cycloalkyl, aryl, substituted aryl, substituted C1-C8 straight or branched alkyl, substituted C3-C8 cycloalkyl; the substituents on the substituted aryl, substituted C1-C8 straight or branched alkyl and substituted C3-C8 cycloalkyl are selected from halogen, amino, amine, nitro, carboxyl, phenyl, benzyl, =O, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy; R2 is selected from hydrogen, hydroxyl, C1-C8 alkoxy, halogen, C1-C8 alkyl, nitro, amine, and amino; the number of R2 is 1-4, and any substitution is at positions 1-4.

2. The use according to claim 1, characterized in that: R1 is selected from C1-C5 straight or branched alkyl, halogenated C1-C5 straight or branched alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, substituted phenyl; the structure of the substituted phenyl is: The number of substituents R5 on the substituted phenyl group is 1-5, and R5 is selected from halogen, amino, nitro, carboxyl, ester, phenyl, benzyl, =O, halogenated alkyl, C1-C5 straight chain or branched alkyl, amine-substituted C1-C5 straight chain or branched alkoxy, alkenyl, alkynyl, hydroxyl, amide, C1-C5 straight chain or branched alkoxy; R4 is selected from C1-C5 straight chain or branched alkylene, carbonyl, amide, halogenated C1-C5 straight chain or branched alkylene.

3. The use according to claim 2, characterized in that: R5 is selected from hydroxy, halogen, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl, carboxyl, ester, aminoethoxy , aminopropyloxy, aminobutyloxy; R4 is selected from methylene, ethylene, n-propylene, 2-propylene, n-butylene, isobutylene, tert-butylene, pentylene, isopentylene, tert-pentylene, halogenated methylene, halogenated ethylene, halogenated n-propylene, halogenated 2-propylene, halogenated n-butylene, halogenated isobutylene, halogenated tert-butylene, halogenated pentylene, halogenated isopentylene, halogenated tert-pentylene.

4. The use according to claim 1, characterized in that: R1 is selected from methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halomethyl, haloethyl, halo-n-propyl, halo-2-propyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halopentyl, halo-isopentyl, halo-tert-pentyl, H, phenyl, 3,4,5-trimethoxyphenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4, 5-trimethoxybenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-hydroxybenzyl, 3-bromo-4-methoxybenzyl, 3-bromo-4-hydroxybenzyl, 2-bromo-3,4,5-trimethoxybenzyl, α-bromoethyl, α-bromobenzyl, α-hydroxyethyl, α-hydroxybenzyl, α-hydroxy-3,4-dimethoxybenzyl, acetyl, benzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenzoyl.

5. The use according to claim 1, characterized in that: R2 is selected from hydrogen, hydroxyl, C1-C5 alkoxy, halogen, C1-C5 alkyl, nitro, amine, and amino; the number of R2 is 1-4, and any substitution is at positions 1-4.

6. The use according to claim 1, characterized in that: The structural formula of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative is as follows: R1 is selected from hydrogen, C1-C8 straight chain or branched alkyl, C3-C8 cycloalkyl, aryl, substituted aryl, substituted C1-C8 straight chain or branched alkyl, substituted C3-C8 cycloalkyl; the substituents on the substituted aryl, substituted C1-C8 straight chain or branched alkyl and substituted C3-C8 cycloalkyl are selected from halogen, amino, amine, nitro, carboxyl, phenyl, benzyl, =O, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyl, alkoxy, carboxyl, ester, aminoethoxy, aminopropoxy, aminobutoxy.

7. R3 is selected from hydrogen, 1-5 carbonyloxy, halogen, C1-C8 alkyl. 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivatives, characterized in that: Its structural formula is as follows: wherein X is selected from oxygen or sulfur atoms; R10 and R11 are independently selected from H, C1-C8 alkyl, amine, and amine-substituted alkyl; R12 is selected from hydrogen, C1-C8 straight or branched alkyl, C3-C8 cycloalkyl, amine, aminealkyl, aryl, substituted aryl, substituted C1-C8 straight or branched alkyl, substituted C3-C8 cycloalkyl; the substituents on the substituted aryl, substituted C1-C8 straight or branched alkyl and substituted C3-C8 cycloalkyl are selected from halogen, amino, amine, nitro, carboxyl, phenyl, benzyl, =O, halogenated C1-C8 straight or branched alkyl, C1-C8 straight or branched alkyl, alkenyl, alkynyl, hydroxyl, alkoxy; the number of substituents on the substituted aromatic heterocycle and substituted aryl is 1-5, and any substitution is at positions 1-5.

8. The 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivative according to claim 7, characterized in that: Each substituent on the substituted aromatic heterocycle and the substituted aromatic group is independently selected from the group consisting of methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated 2-propyl, halogenated n-butyl, halogenated isobutyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated tert-pentyl, methyl formate, ethyl formate, propyl formate, butyl formate, pentyl formate, hexyl formate, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

9. The method for preparing a 3-substituted naphtho[2,3-b]isoxazole-4,9-dione derivative according to claim 7 or 8, characterized in that: When X is an oxygen atom, the process comprises the following steps: S1, raw material 4 undergoes substitution reaction under the action of acetic anhydride and sodium hydroxide, and then undergoes oxidation reaction under the action of hydrochloric acid and potassium dichromate to generate intermediate 5; S2, raw material 3 and hippuric acid react under the action of sodium acetate and acetic anhydride as solvent to obtain intermediate 6; S3, intermediate 5 and intermediate 6 undergo a ring-closing reaction to obtain the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative; The structural formulas of the raw materials and intermediates are as follows:

10. Use of the 3-substituted naphtho[2,3-b]isothiazole-4,9-dione derivative according to claim 7 or 8 in the preparation of anti-psoriasis or anti-tumor drugs.

Citation Information

Patent Citations

  • Kinase inhibitors useful for the treatment of proliferative diseases

    CN101516379A

  • Naphtho-[2,3-b]isoxazole-4,9-diketone derivatives as well as preparation method and application thereof

    CN108794419A

  • 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

    CN1756547A

  • Tumour phenotype patient selection method

    WO2012052757A1